Staar Surgical Company has recently announced a merger with Alcon, a move that is expected to maximize value for the stockholders of Staar Surgical. The company filed its definitive proxy statement on schedule 14A on September 16, 2025, and the proxy statement was sent to stockholders on the same day.
Through this merger, Staar Surgical is aiming to create value for its stockholders. It is important to note that this presentation is not a substitute for the proxy statement or any other document that Staar may file with the SEC or send to its stockholders in connection with the proposed transaction. The company urges stockholders to read all relevant documents filed or to be filed with the SEC, including the proxy statement, as they will contain important information about the proposed transaction.
In connection with the merger, Staar Surgical has disclosed certain information about the directors and executive officers of the company, including their ownership of Staar's common stock, in the definitive proxy statement for Staar's 2025 annual meeting of stockholders. This information is available in the sections captioned "compensation of directors," "information regarding executive officers" and "security ownership of principal shareholders and management."
Staar Surgical has emphasized the importance of understanding the details of the proposed transaction before making any voting decision. It has also provided information about the participants in the proxy solicitation and their direct and indirect interests, by security holdings or otherwise, which will be contained in other relevant materials to be filed with the SEC in respect of the proposed transaction when they become available. Following these announcements, the company's shares moved -0.07%, and are now trading at a price of $26.75. For the full picture, make sure to review STAAR SURGICAL CO's 8-K report.
